$RAPH
Raphael Pharmaceutical Inc.

2024 Q4 Form 10-Q Financial Statement

#000121390024098456 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3 2023 Q4
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $157.0K
YoY Change
% of Gross Profit
Research & Development $162.0K
YoY Change -68.24%
% of Gross Profit
Depreciation & Amortization $0.00
YoY Change
% of Gross Profit
Operating Expenses $162.0K
YoY Change -68.24%
Operating Profit -$319.0K
YoY Change -56.24%
Interest Expense -$7.000K
YoY Change
% of Operating Profit
Other Income/Expense, Net -$7.000K
YoY Change -275.0%
Pretax Income -$326.0K
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$326.0K
YoY Change -55.03%
Net Earnings / Revenue
Basic Earnings Per Share $0.01
Diluted Earnings Per Share $0.01
COMMON SHARES
Basic Shares Outstanding 18.70M shares 18.70M shares 18.10M shares
Diluted Shares Outstanding 18.70M shares

Balance Sheet

Concept 2024 Q4 2024 Q3 2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $40.00K
YoY Change
Cash & Equivalents $40.00K $230.0K
Short-Term Investments
Other Short-Term Assets $9.000K $107.0K
YoY Change -91.26% 148.84%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $49.00K $337.0K
YoY Change -87.81% 1.81%
LONG-TERM ASSETS
Property, Plant & Equipment $2.000K $2.000K
YoY Change 0.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $2.000K $2.000K
YoY Change 100.0% 0.0%
TOTAL ASSETS
Total Short-Term Assets $49.00K $337.0K
Total Long-Term Assets $2.000K $2.000K
Total Assets $51.00K $339.0K
YoY Change -87.34% 1.8%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $537.0K
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $130.0K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $667.0K $72.00K
YoY Change 39.54% -68.28%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $667.0K $72.00K
Total Long-Term Liabilities $0.00
Total Liabilities $667.0K
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$8.434M -$7.310M
YoY Change 13.48% 21.33%
Common Stock $7.818M $7.577M
YoY Change 4219.34% 4726.11%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$616.0K -$267.0K
YoY Change
Total Liabilities & Shareholders Equity $51.00K $339.0K
YoY Change -87.34% 1.8%

Cashflow Statement

Concept 2024 Q4 2024 Q3 2023 Q4
OPERATING ACTIVITIES
Net Income -$326.0K
YoY Change -55.03%
Depreciation, Depletion And Amortization $0.00
YoY Change
Cash From Operating Activities -$80.00K
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -80.00K
Cash From Investing Activities
Cash From Financing Activities 0.000
Net Change In Cash -80.00K
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$80.00K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-53002
dei Entity Registrant Name
EntityRegistrantName
Raphael Pharmaceutical Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-0204284
dei Entity Address Address Line1
EntityAddressAddressLine1
4 Lui Paster Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Tel Aviv-Jaffa
dei Entity Address Country
EntityAddressCountry
IL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
6803605
dei City Area Code
CityAreaCode
(+972)
dei Local Phone Number
LocalPhoneNumber
52-775-5072
dei Security12b Title
Security12bTitle
N/A
dei No Trading Symbol Flag
NoTradingSymbolFlag
true
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
18701418 shares
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
40000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
230000 usd
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
9000 usd
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
107000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
49000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
337000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2000 usd
CY2024Q3 us-gaap Assets
Assets
51000 usd
CY2023Q4 us-gaap Assets
Assets
339000 usd
CY2024Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
537000 usd
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
34000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
667000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
72000 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
21020560 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18701418 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18701418 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18502918 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18502918 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
187000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
185000 usd
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
7631000 usd
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
7392000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-8434000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-7310000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-616000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
267000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
51000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
339000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
565000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
917000 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
162000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
510000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
550000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
489000 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
157000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
219000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-1115000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-1406000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-319000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-729000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-9000 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-7000 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4000 usd
us-gaap Net Income Loss
NetIncomeLoss
-1124000 usd
us-gaap Net Income Loss
NetIncomeLoss
-1406000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-326000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-725000 usd
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.06
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.06
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.09
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.09
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.01
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.01
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.04
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.04
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18646942 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18646942 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16174658 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16174658 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18701418 shares
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18701418 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16444399 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16444399 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
267000 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
180000 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
61000 usd
us-gaap Net Income Loss
NetIncomeLoss
-798000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-290000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-326000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-616000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
106000 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
314000 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
200000 usd
us-gaap Net Income Loss
NetIncomeLoss
-681000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-61000 usd
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
711000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-725000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-75000 usd
us-gaap Net Income Loss
NetIncomeLoss
-1124000 usd
us-gaap Net Income Loss
NetIncomeLoss
-1406000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
61000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
2000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-40000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
595000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
251000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-470000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1115000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
280000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1126000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
280000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1126000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-190000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
11000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
230000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
288000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
40000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
299000 usd
us-gaap Nature Of Operations
NatureOfOperations
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 1:- GENERAL</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">a.</td><td style="text-align: justify">Raphael Pharmaceutical Inc. (formerly Easy Energy, Inc.) (the “Company”) was incorporated under the laws of the State of Nevada on May 17, 2007. The Company is headquartered in Tel Aviv-Jaffa, Israel. From April 1, 2011 until December 31, 2019, the Company was not active.</td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On October 8, 2020, the Company and its stockholders entered into a Share Exchange Agreement (the “Share Exchange”) with an Israeli pharmaceutical company (“Raphael”), according to which, among other matters, all shareholders of Raphael will sell and convey the entire holdings in Raphael to the Company such that following the Share Exchange, the shareholders of Raphael will hold 90% of the issued and outstanding common stock of the Company, and the existing shareholders of the Company will hold the remaining 10% of the issued and outstanding common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On May 14, 2021, the Company’s board of directors and stockholders approved a 1-for-100 reverse split of the Company’s common stock, which was implemented and became effective as of May 14, 2021. The reverse split combined each one hundred (100) shares of the Company’s issued and outstanding common stock into one share of common stock. No fractional shares were issued in connection with the reverse split, and any fractional shares resulting from the reverse split were rounded up to the nearest whole share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On May 14, 2021, Raphael and the Company completed the Share Exchange pursuant to which 9,459,253 common stock were issued to the shareholders of Raphael so that they became the holders of 90% of the issued and outstanding common stock of the Company immediately after the Share Exchange while the Company’s shareholders held, following the Share Exchange, 1,051,028 common stock which represents 10% of the Company. On May 19, 2021, as agreed by the parties to the Share Exchange, the Company changed its name to Raphael Pharmaceutical Inc. Following such Share Exchange, Raphael’s activities are the sole activities of the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Share Exchange was accounted for as a reverse recapitalization which is outside the scope ASC 805, “Business Combinations” (“ASC 805”), as the Company, the legal acquirer, is considered a non-operating public shell, and is therefore not a business as defined in ASC 805. As the shareholders of Raphael received the largest ownership interest in the Company, Raphael was determined to be the “accounting acquirer” in the Share Exchange. As a result, the historical financial statements of the Company were replaced with the financial statement of Raphael for all periods presented.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company’s common stock began public trading on the over-the-counter market in the U.S. in January 2023 under the symbol “RAPH”.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">b.</td><td style="text-align: justify">Going concern and management plans</td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The accompanying financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Since its inception, the Company has devoted substantially all of its efforts to research and development, clinical trials, and raising capital. The Company is still in its development and clinical stage and has not yet generated revenues. The extent of the Company’s future operating losses and the timing of becoming profitable are uncertain. As of September 30, 2024, the Company’s accumulated deficit was $8,434. The Company has funded its operations to date primarily through equity financing and the issuance of a loan. Additional funding will be required to complete the Company’s research and development and clinical trials, to attain regulatory approvals, to begin the commercialization efforts of the Company’s product and to achieve a level of sales adequate to support the Company’s cost structure.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Management’s plans include, but are not limited to, raising capital in the United States. There can be no assurance that it will be able to successfully raise additional financing, including in a public offering, or obtain additional financing on a timely basis or on terms acceptable to the Company, or at all.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Management expects that the Company will continue to generate losses from the development, clinical development and regulatory activities of its product, which will result in negative cash flow from operating activity. This has led management to conclude that substantial doubt about the Company’s ability to continue as a going concern exists in the event that additional funding does not occur. If such sufficient financing is not received timely, the Company will not have sufficient cash flows and liquidity to finance its business operations as currently contemplated and would then need to pursue a plan to license its assets, seek to be acquired by another entity, cease operations and/or seek bankruptcy protection. The Company’s financial statements do not reflect any adjustments that might result from the outcome of this uncertainty.</p>
CY2020Q4 raph Percentage Of Share Capital Issued
PercentageOfShareCapitalIssued
0.90 pure
CY2020Q4 raph Percentage Of Share Capital Outstanding
PercentageOfShareCapitalOutstanding
0.90 pure
CY2020Q4 raph Common Stock Percentage
CommonStockPercentage
0.10 pure
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
The reverse split combined each one hundred (100) shares of the Company’s issued and outstanding common stock into one share of common stock.
CY2021Q2 raph Percentage Of Share Capital Issued
PercentageOfShareCapitalIssued
0.90 pure
CY2021Q2 raph Percentage Of Share Capital Outstanding
PercentageOfShareCapitalOutstanding
0.90 pure
CY2021Q2 us-gaap Stockholders Equity Note Changes In Capital Structure Subsequent Changes To Number Of Common Shares
StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares
1051028 shares
CY2021Q2 raph Common Stock Percentage
CommonStockPercentage
0.10 pure
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-8434000 usd
CY2024Q1 us-gaap Stock Issued During Period Shares Other
StockIssuedDuringPeriodSharesOther
58500 shares
CY2024Q1 us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
50000 usd
CY2024Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
40000 shares
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
usd
us-gaap Share Based Compensation
ShareBasedCompensation
usd
us-gaap Depreciation
Depreciation
usd
us-gaap Depreciation
Depreciation
usd
raph Proceeds From Advance Payment On Account Of Shares
ProceedsFromAdvancePaymentOnAccountOfShares
usd
raph Proceeds From Advance Payment On Account Of Shares
ProceedsFromAdvancePaymentOnAccountOfShares
usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001415397

Files In Submission

Name View Source Status
0001213900-24-098456-index-headers.html Edgar Link pending
0001213900-24-098456-index.html Edgar Link pending
0001213900-24-098456.txt Edgar Link pending
0001213900-24-098456-xbrl.zip Edgar Link pending
ea0220551-10q_raphael.htm Edgar Link pending
ea022055101ex31-1_raphael.htm Edgar Link pending
ea022055101ex31-2_raphael.htm Edgar Link pending
ea022055101ex32-1_raphael.htm Edgar Link pending
ea022055101ex32-2_raphael.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ea0220551-10q_raphael_htm.xml Edgar Link completed
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
raph-20240930.xsd Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
raph-20240930_cal.xml Edgar Link unprocessable
raph-20240930_def.xml Edgar Link unprocessable
raph-20240930_lab.xml Edgar Link unprocessable
raph-20240930_pre.xml Edgar Link unprocessable